Beam Therapeutics Inc. (BEAM) Free cash flow
- Free cash flow · 12 months (USD): Value $-372.77M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -238.90%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-372.77M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-359.38M − $13.39M ≈ $-372.77M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -238.90% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-372.77M ÷ $156.03M × 100 ≈ -238.90% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-359.38M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 4.15× | Operating cash flow / net income. Period ending 2026-06-30. $-359.38M ÷ $-86.52M ≈ 4.15× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -359.38M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 13.39M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -372.77M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 156.03M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -86.52M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-372.77M | (m) | $-359.38M | $13.39M | (m) | $156.03M | (m) | $-86.52M | (m) | (m) | -238.90% | 4.15× |
| 2026-03-31 | $-383.84M | (m) | $-369.73M | $14.11M | (m) | $164.01M | (m) | $-65.98M | (m) | (m) | -234.04% | 5.60× |
| 2025-12-31 | $-360.05M | (m) | $-345.10M | $14.95M | (m) | $139.74M | (m) | $-79.99M | (m) | (m) | -257.65% | 4.31× |
| 2025-09-30 | $-352.36M | (m) | $-338.18M | $14.18M | (m) | $55.70M | (m) | $-414.64M | (m) | (m) | -632.59% | 0.82× |
| 2025-06-30 | $-355.57M | (m) | $-344.82M | $10.75M | (m) | $60.27M | (m) | $-398.58M | (m) | (m) | -589.95% | 0.87× |
| 2025-03-31 | $-360.96M | (m) | $-351.38M | $9.57M | (m) | $63.58M | (m) | $-387.34M | (m) | (m) | -567.74% | 0.91× |
| 2024-12-31 | $-356.19M | (m) | $-347.25M | $8.95M | (m) | $63.52M | (m) | $-376.74M | (m) | (m) | -560.77% | 0.92× |
| 2024-09-30 | $-145.37M | (m) | $-135.81M | $9.56M | (m) | $349.64M | (m) | $-143.59M | (m) | (m) | -41.58% | 0.95× |
| 2024-06-30 | $-153.40M | (m) | $-137.47M | $15.94M | (m) | $352.57M | (m) | $-143.01M | (m) | (m) | -43.51% | 0.96× |
| 2024-03-31 | $-169.28M | (m) | $-139.13M | $30.15M | (m) | $360.91M | (m) | $-134.74M | (m) | (m) | -46.90% | 1.03× |
| 2023-12-31 | $-182.93M | (m) | $-149.19M | $33.73M | (m) | $377.71M | (m) | $-132.53M | (m) | (m) | -48.43% | 1.13× |
| 2023-09-30 | $-391.86M | (m) | $-353.46M | $38.40M | (m) | $81.55M | (m) | $-313.67M | (m) | (m) | -480.50% | 1.13× |
| 2023-06-30 | $-380.41M | (m) | $-338.17M | $42.24M | (m) | $80.16M | (m) | $-327.16M | (m) | (m) | -474.57% | 1.03× |
| 2023-03-31 | $-353.49M | (m) | $-305.78M | $47.71M | (m) | $76.70M | (m) | $-316.33M | (m) | (m) | -460.89% | 0.97× |
| 2022-12-31 | $-26.42M | (m) | $22.53M | $48.95M | (m) | $60.92M | (m) | $-289.09M | (m) | (m) | -43.37% | -0.08× |
| 2022-09-30 | $39.49M | (m) | $93.55M | $54.06M | (m) | $91.95M | (m) | $-315.45M | (m) | (m) | 42.95% | -0.30× |
| 2022-06-30 | $123.00M | (m) | $171.05M | $48.05M | (m) | $76.92M | (m) | $-233.99M | (m) | (m) | 159.91% | -0.73× |
| 2022-03-31 | $148.21M | (m) | $190.80M | $42.59M | (m) | $60.27M | (m) | $-238.29M | (m) | (m) | 245.91% | -0.80× |
| 2021-12-31 | $-113.08M | (m) | $-66.27M | $46.81M | (m) | $51.84M | (m) | $-370.64M | (m) | (m) | -218.11% | 0.18× |
| 2021-09-30 | $-133.96M | (m) | $-92.40M | $41.57M | (m) | $781.00K | (m) | $-401.39M | (m) | (m) | -17152.75% | 0.23× |
| 2021-06-30 | $-155.22M | (m) | $-116.62M | $38.61M | (m) | $24.00K | (m) | $-407.73M | (m) | (m) | -646758.33% | 0.29× |
| 2021-03-31 | $-131.72M | (m) | $-106.93M | $24.79M | (m) | $24.00K | (m) | $-365.69M | (m) | (m) | -548812.50% | 0.29× |
| 2020-12-31 | $-112.10M | (m) | $-95.74M | $16.36M | (m) | $24.00K | (m) | $-194.59M | (m) | (m) | -467075.00% | 0.49× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-84.52M | (m) | $-72.00M | $12.52M | (m) | $18.00K | (m) | $-78.33M | (m) | (m) | -469561.11% | 0.92× |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |